Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data

Published: Mar 09, 2023 By Kate Goodwin

 

Pictured: Clene CEO Rob Etherington/company courtesy

Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients.

In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted ALS Functional Rating Scale-Revised.

However, the strong survival signals seen at six months warranted a deeper look.

 Original article

Comments

Popular posts from this blog

Researchers define protocol for high-resolution imaging of living cells using atomic force microscopy

Supercomputer decodes protein ‘language,’ offering new clues to fight cancer

First map of every neuron in an adult brain has been produced for a fruit fly